RE:RE:RE:RE:RE:RE:Pomerantz Law Investigation
These days since December 2 are excreedingly painful, but i tried to be rational.
Literature reported that multi-mechasisms involved in the docetaxel-resistance in cancer cells. For example, most mutation in the docetaxel binding site on tunulin are thought to mediate resistance by iducing reduced affinity of the docetaxel-tubulin binding. (Refer is here. https://cdrjournal.com/article/view/3613)
Therefore, for those patients who have been treated with docetaxel, docetaxel maybe no longer efficient to kill cancer cells. And i agree with you that as long as they can demonstrate the proof of concept, the plateform is still extremely valiuable. If the proof of concept is provided, they can use more validated chemicals, such as SN38 or isotope rather than docetaxel.
The dosing regimen is interesting. For Trodelvy (sacituzumab-govitecan), MTD is 12 mg/kg, half life is 18 hours, paticipants received sacituzumab-govitecan 8mg/kg on day1 and day8 of a 21 day treatment cycle. For TH1902, i guess the half life is less than 6 hours, patients to receive MTD of Th1902 (1.5x docetaxel) once every cycle (21 days) is probably less efficient to kill cancer cells since TH1902 woul be cleaned within few hours. In consideration of short half life. If they treat patient with 1x docetaxel of TH1902 once weekly, the toxcity might be weaker and efficacy might be better. But if they do this way, the retention rate is my concern. I am not sure if those patients can tolerate the frequent moving from home to hospital since they are all sick heavily.